2-Chlorophenol

2-Chlorophenol

SCHEMBL6877895

CCOC(=O)c1cnc(SC)nc1Oc1ccccc1Cl.Oc1ccccc1Cl

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
HPGD P15428 2/20 0.59
ALDH1A1 P00352 8/20 0.59
NPSR1 Q6W5P4 4/20 0.59
KMT2A Q03164 2/20 0.59
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
POLB P06746 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
HTT P42858 1/20 0.51
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CYP1A2 P05177 3/20 0.47
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SYK P43405 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guaiacol SCHEMBL6878387 0.84 ALDH1A1 (0.54) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL6880252 0.84 ALDH1A1 (0.60) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL6881377 0.81 GPBAR1 (0.52) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL31467164 0.80 ALDH1A1 (0.69) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL11009450 0.80 ALDH1A1 (0.69) MAPTHPGDALDH1A1NPSR1KMT2A
Phenol SCHEMBL6873017 0.79 ALDH1A1 (0.65) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL5111739 0.78 CYP1A2 (0.75) MAPTALDH1A1NPSR1KMT2ALMNA
SCHEMBL3278294 0.76 MEN1 (0.61) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL31148410 0.76 MEN1 (0.61) MAPTHPGDALDH1A1NPSR1KMT2A
SCHEMBL6879275 0.75 NPSR1 (0.63) MAPTHPGDALDH1A1NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 MAPT 4715/4885HPGD 1638/4885ALDH1A1 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.